scholarly journals Lack of omalizumab efficacy in severe atopic dermatitis with extremely elevated IgE levels: two case reports and a literature review

2019 ◽  
Vol 28 (2) ◽  
Author(s):  
Miroslav Nečas ◽  
Vladimír Vašků ◽  
Eva Březinová
Keyword(s):  
Atopic Dermatitis ◽  
Literature Review ◽  
Case Reports ◽  
Severe Atopic Dermatitis

scholarly journals 4CPS-025 Dupilumab in the treatment of moderate to severe atopic dermatitis: case reports

2020 ◽  
Author(s):  
C Palomo-Palomo ◽  
MM Romero Alonso ◽  
D Guerra Estevez ◽  
M Barrera Ledesma ◽  
J Estaire Gutierrez
Keyword(s):  
Atopic Dermatitis ◽  
Case Reports ◽  
Severe Atopic Dermatitis

scholarly journals Efficacy and safety of dupilumab in adult moderate-to-severe atopic dermatitis: An update narrative literature review

2022 ◽  
Vol 13 (1) ◽  
pp. 6-15
Author(s):  
Magdalini Kreouzi ◽  
Nikolaos Theodorakis ◽  
Ekatherine Prokopiou ◽  
Elena Thomaidou
Keyword(s):  
Atopic Dermatitis ◽  
Literature Review ◽  
Biologic Agent ◽  
Severe Atopic Dermatitis ◽  
Therapeutic Effects ◽  
Topical Corticosteroids ◽  
Mesh Terms ◽  
Narrative Literature ◽  
Narrative Literature Review

Background: Adult atopic dermatitis (AD) is defined as a continuum of childhood AD or the development of the disease in adulthood, accounting for 7.7–59.7% of adult AD cases varying in severity and manifestations. The symptomatology of moderate-to-severe adult AD may significantly impact the overall health and quality of life of the patient. The “classic” topical treatments used in mild-to-moderate cases, such as emollients and topical corticosteroids, are usually not adequate to control the symptoms of most of the patients with moderate-to-severe disease. For many years these patients were managed with systemic corticosteroids and immunomodulators, leading to substantial side effects with questionable efficacy. The introduction of dupilumab, the first biologic agent approved by the Food and Drug Administration for use in adult moderate-to-severe AD, has commenced a new era in the management of AD. This narrative literature review addresses the question of how patients with moderate-to-severe AD may achieve a recession or improvement in the overall progression of the disease with the use of dupilumab in both an efficient and safe way. Material and Methods: A search in the PubMed, Embase, and Cochrane databases was conducted using the following combination of MeSH terms: “dupilumab” AND “atopic” (“dermatitis” OR “eczema”). The searches were limited to RCTs written in the English language published before January 25, 2021. The literature used included phase II and III RCTs examining the efficacy and/or safety of dupilumab compared to placebo or other treatments in adults with moderate-to-severe AD. Moderate-to-severe AD was defined by an IGA score of 3 (moderate) or 4 (severe) and EASI 16 or higher at screening and baseline. Additionally, we searched the website clinicaltrials.gov for any unpublished or ongoing RCTs. The search was done independently by two authors in all databases and followed by the exclusion of duplicates. Results: Upon reviewing all randomized controlled trials, dupilumab was found to be an effective and safe option for managing adult moderate-to-severe AD with long-term therapeutic effects. Conclusion: The best results for maintaining long-term disease recession were achieved with the combination of dupilumab and topical corticosteroids.

Sign in / Sign up

Export Citation Format

Share Document